课题基金 / 基金详情

项目摘要

项目成果

MICHAEL Allan HOLINSTAT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Michigan Institute for Clinical & Health Research (MICHR) recognizes the need for a highly skilled, diverse workforce that can conduct impactful clinical and translational research that improves health. Since the inception of MICHR, the development of a diverse translational workforce has been a consistent priority. This priority includes engaging pre-doctoral trainees within their first few years of training and providing direct experience partnered with specific didactic training. Developed over the course of a decade, our current TL1- supported training programs include a short-term component (Summer Immersion Program) and a long-term component (the Master of Science in Clinical Research Program [MSCR]). This proposal requests support for 10 short-term trainees and 10 long-term trainees (an increase of one trainee) each year. Trainees will comprise a mixture of pre-professional doctoral students (e.g., medical student) and post-professional degree trainees. Other goals include: 1. Providing more opportunities for TL1 trainees to participate in community based research. 2. Supporting trainee career development by formally educating faculty mentors on mentoring skills using the curricula from the National Research Mentoring Network. 3. Expanding the network supporting the development of MSCR trainees. 4. Providing more intern/externship experiences for TL1 trainees. 5. Developing, demonstrating, and disseminating competency-based assessments for all TL1 trainees to improve the measurement of translational research skills. These five key goals will allow the MICHR TL1 programs to effectively train the next generation of translational scientists. The goal is that, upon program completion, these trainees will be highly engaged and motivated to continue work in clinical and translational research, competent in the skills necessary for clinical-translational research, experienced members of multidisciplinary or interprofessional teams led by highly skilled and engaged mentors, and nuanced in their capability to successfully participate in community based research.
期刊论文(59)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.amjmed.2021.06.018
发表时间: 2021-12
期刊: The American journal of medicine
影响因子: --
作者: [Garfein J, Cholack G, Krallman R, Feldeisen D, Montgomery D, Kline-Rogers E, Eagle K, Rubenfire M, Bumpus S]
通讯作者: Bumpus S
A Rare Case Report of Neurological Condition: Moersch-Woltman Syndrome with Positive Anti-GAD Antibodies.
神经系统疾病罕见病例报告:抗 GAD 抗体呈阳性的 Moersch-Woltman 综合征。
DOI: --
发表时间: 2023
期刊: International journal of medical students
影响因子: --
作者: [Pitliya,Aakanksha]
通讯作者: Pitliya,Aakanksha
Visual Field Defect Patterns Associated With Lesions of the Retrochiasmal Visual Pathway.
与视交叉后视觉通路病变相关的视野缺陷模式。
DOI: 10.1097/wno.0000000000001601
发表时间: 2022
期刊: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
影响因子: --
作者: [Cho,Juno, Liao,Eric, Trobe,JonathanD]
通讯作者: Trobe,JonathanD
DOI: 10.1111/ajd.13897
发表时间: 2022-11
期刊: AUSTRALASIAN JOURNAL OF DERMATOLOGY
影响因子: 2
作者: [Ryder, C. Yoonhee, Matthews, Natalie H., Lowe, Lori, Wang, Frank]
通讯作者: Wang, Frank
42
    2022 Midwest Platelet Conference
    Biomarkers for 12-lipoxygenase inhibition as a therapeutic intervention for heparin-induced thrombocytopenia and thrombosis (HIT/T)
    • 批准号:
      10427382
    • 项目类别:
    • 资助金额:
      $23.36万
    • 财政年份:
      2021
    • 负责人:
      MICHAEL Allan HOLINSTAT
    • 依托单位:
    Biomarkers for 12-lipoxygenase inhibition as a therapeutic intervention for heparin-induced thrombocytopenia and thrombosis (HIT/T)
    • 批准号:
      10177358
    • 项目类别:
    • 资助金额:
      $20.86万
    • 财政年份:
      2021
    • 负责人:
      MICHAEL Allan HOLINSTAT
    • 依托单位:
    12-HETrE regulation of blood coagulation, hemostasis, and thrombosis
    海外基金